CHICAGO, June 13, 2024 – The American Bar Association is pleased that the Supreme Court today unanimously rejected a challenge to the FDA decisions regulating the drug mifepristone because plaintiffs lack standing. The case is U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine.
The ABA remains committed to supporting reproductive choice. Limiting this choice can have devastating consequences for those who are pregnant and can adversely affect their physical and mental health, their lives and the lives of their families. Today’s ruling maintains the availability of mifepristone as an option for individuals and families that need it.
The ABA is the largest voluntary association of lawyers in the world. As the national voice of the legal profession, the ABA works to improve the administration of justice, promotes programs that assist lawyers and judges in their work, accredits law schools, provides continuing legal education, and works to build public understanding around the world of the importance of the rule of law. View our privacy statement online. Follow the latest ABA news at www.americanbar.org/news and on X (formerly Twitter) @ABANews.